Trial reportDigestive diseases and sciences2007
Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients.
Trial report in Digestive diseases and sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019.Clinical pharmacokinetics · 2020Pooled it
- Vitamin E supplementation in people with cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Oral calorie supplements for cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin E supplementation in people with cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Oral protein calorie supplementation for children with chronic disease.The Cochrane database of systematic reviews · 2015Pooled it
- Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers.Orphanet journal of rare diseases · 2010Guideline
- Trial
- Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial.American journal of respiratory and critical care medicine · 2018Trial
- Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis.JPEN. Journal of parenteral and enteral nutrition · 2017Trial
- Effect of a vitamin/mineral supplement on children and adults with autism.BMC pediatrics · 2011Trial
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status in 2 to 5 Year-Old Children Using a Cystic Fibrosis-Specific Multivitamin Formulation.Children (Basel, Switzerland) · 2026Article
- Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children.Children (Basel, Switzerland) · 2025Article
- Article
- α-Tocopherol Pharmacokinetics in Adults with Cystic Fibrosis: Benefits of Supplemental Vitamin C Administration.Nutrients · 2022Article
- Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial.Journal of clinical medicine · 2022Article
- Antioxidant supplementation for lung disease in cystic fibrosis.The Cochrane database of systematic reviews · 2019Review
- Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease.Journal of lipid research · 2018Article
- Article
- Mechanisms for the prevention of vitamin E excess.Journal of lipid research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cystic fibrosis (CF), pancreatic insufficiency and a diminished bile acid pool cause malabsorption of important nutrients and dietary components leading to deficiency, poor nutritional status, and oxidative stress. Of particular significance is the malabsorption of fat-soluble nutrients and antioxidants, which are important for normal immune and neurologic function. Patients with CF often are deficient in these compounds despite supplementation with the current standard of care therapy. The objective was to compare the pharmacokinetic profile of this water-soluble vitamin E formulation (Aqua-E) with an oil-based softgel formulation in a malabsorbing patient population. Patients with CF who had documented malabsorption were recruited for participation in this pharmacokinetic study. Patients who met inclusion and exclusion criteria discontinued vitamin E supplementation, except for that in a multivitamin, for 7 to 21 days before the day of dosing. Patients were randomized to a single dose of 20 ml of Aqua-E or three oil-based softgels, which contained equivalent amounts of tocopherols. Blood was drawn from patients at time 0, 2, 4, 8, 24, 48, and 168 hr and analyzed for tocopherols. Eight patients were enrolled in the study and randomized to Aqua-E or softgels. The primary outcome, the absorption of gamma-tocopherol in Aqua-E (AUC=115 micro g/ml(*)hr), was significantly greater than that of oil-based softgels (AUC=25.3 micro g/ml(*)hr; P=0.013). Total-tocopherols (alpha+gamma+delta) in Aqua-E (AUC=294 micro g/ml(*)hr) showed a strong trend toward increased absorption compared with that of oil-based softgels (AUC=117 micro g/ml(*)hr; P=0.09). In conclusion, this novel, water-soluble formulation showed a marked and statistically significant increase in absorption of gamma-tocopherol in malabsorbing patients with CF compared with an oil-based formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.